Latest News for: gpr17

Edit

Rewind Therapeutics Secures Additional Financing to Advance Oral GPR17 Remyelination Program

Nasdaq Globe Newswire 06 Oct 2026
Rewind Therapeutics secures financing to advance its oral GPR17 remyelination program for MS, supported by peer-reviewed preclinical data in PLOS ONE ... .
  • 1

Article Search

tools
×
×
×
×